530084-77-6

Upstream product

• 530084-80-1 8-benzyloxy-5-[(R)-2-[2-(4-bromo-phenyl)-ethylamino]-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-1H-quinolin-2-one hydrochloride 
• 92028-21-2 4-methoxy-3-phenylaniline hydrochloride 
• 530084-74-3 (R)-8-(benzyloxy)-5-(2-bromo-1-((tert-butyldimethylsilyl)oxy)ethyl)quinolin-2(1H)-one 
• 771472-41-4 2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethylamine 

Downstream Products

• 530084-78-7 N-[2-[4-[(3-phenyl-4-methoxyphenyl)amino]phenyl]ethyl]-(R)-2-hydroxy-2-(8-benzyloxy-1,2-dihydro-2-oxoquinolin-5-yl)ethylamine 

Relevant academic research and scientific papers

Crystalline form of aryl aniline beta-2 adrenergic receptor agonist

The invention provides crystalline solvate forms of a salt of a novel β2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the solvate forms, formulations containing the pharmaceutical compositions,

Aryl aniline beta2 adrenergic receptor agonists

The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.